Financials in USD. Standardized financial statements.
A compact view of how Protalix BioTherapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $52.74M | $53.40M | $65.49M | $47.64M | $38.35M | $62.90M | $54.69M | $34.24M | $21.08M | $9.20M |
| Revenue Growth? | -1.2% | -18.5% | +37.5% | +24.2% | -39.0% | +15.0% | +59.7% | +62.4% | +129.1% | 0.0% |
| Cost of Revenue? | $27.51M | $24.32M | $22.98M | $19.59M | $16.35M | $10.87M | $10.89M | $9.30M | $15.23M | $8.40M |
| Gross Profit? | $25.24M | $29.08M | $42.51M | $28.05M | $22.00M | $52.02M | $43.80M | $24.94M | $5.85M | $801,000 |
| Gross Margin? | +47.8% | +54.5% | +64.9% | +58.9% | +57.4% | +82.7% | +80.1% | +72.8% | +27.7% | +8.7% |
| Operating Expenses? | $30.74M | $25.16M | $32.05M | $41.06M | $42.46M | $49.31M | $54.52M | $44.25M | $40.36M | $33.96M |
| Operating Income? | -$5.50M | $3.92M | $10.46M | -$13.01M | -$20.46M | $2.71M | -$10.72M | -$19.31M | -$34.52M | -$33.16M |
| EBITDA? | -$4.04M | $6.52M | $12.94M | -$10.78M | -$18.94M | $4.45M | -$8.69M | -$17.10M | -$71.80M | -$23.00M |
| Income Before Tax | -$5.61M | $4.15M | $8.57M | -$14.40M | -$27.58M | -$6.52M | -$18.28M | -$26.46M | -$83.44M | -$29.18M |
| Income Tax Expense | $996,000 | $1.22M | $254,000 | $530,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$6.60M | $2.93M | $8.31M | -$14.93M | -$27.58M | -$6.52M | -$18.28M | -$26.46M | -$83.44M | -$29.36M |
| EPS? | $-0.08 | $0.04 | $0.12 | $-0.31 | $-0.62 | $-0.22 | $-1.23 | $-1.80 | $-6.50 | $-0.29 |
| Diluted EPS? | $-0.08 | $0.04 | $0.10 | $-0.31 | $-0.62 | $-0.22 | $-1.23 | $-1.80 | $-6.50 | $-0.29 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality